Betadex sulfobutyl ether sodium is a polyanionic β-cyclodextrin derivative supplied as a white to off-white amorphous powder with an average degree of substitution of 6.2–6.9 sulfobutyl ether groups per macrocycle. The material functions as a compendial-grade functional excipient in parenteral, oral, and ophthalmic dosage forms, with molecular weight typically above 2000 g/mol and high aqueous solubility. The application profiles below are limited to dosage form categories for which the United States FDA Inactive Ingredient Database lists betadex sulfobutyl ether sodium as a prior-approved component. They address downstream formulation, processing, release testing, and critical boundary conditions rather than general component benefits.

When a Poorly Water-Soluble Injectable Must Be Administered Without Organic Co-Solvents

In aqueous parenteral manufacturing, betadex sulfobutyl ether sodium is incorporated into the bulk concentrate at 10%–40% w/v before terminal dilution. The API-to-SBECD molar ratio is determined by phase-solubility analysis; approved parenteral formulations commonly operate between 1:2 and 1:30, with ratios above 1:50 reserved for drugs exhibiting weak cavity binding. The compounding vessel is a stainless-steel tank with a bottom-mounted impeller operated at 500–1000 rpm in Water for Injection at 15–25°C. SBECD is dissolved first, the active pharmaceutical ingredient is added under high-shear agitation, and pH is adjusted with dilute hydrochloric acid or sodium hydroxide. For heat-stable products, moist-heat terminal sterilization is validated according to ISO 17665-1:2006, typically at 121.1°C for an F0 value of at least 8 min. For heat-labile products, the solution is sterilized through a 0.22 µm sterilizing-grade PVDF or PES filter validated per ASTM F838-20; filter flux must be characterized because SBECD can lower surface tension and alter membrane wetting. Aseptic filling requires EU GMP Annex 1 Grade A conditions within an ISO 14644-1:2015 Class 5 zone. Finished product types include IV infusion concentrates, ready-to-use infusion bags, intramuscular injections, and subcutaneous injections. Release testing is anchored to USP <1>, USP <71>, USP <85>, USP <788>, and USP <790>; particulate burden is a critical failure point because pH excursions and autoclave stress can drive aggregate formation in SBECD-containing solutions. After admixture with normal saline or 5% dextrose, final infusate SBECD concentration in approved products generally falls between 5 mg/mL and 80 mg/mL, depending on the specific drug product and infusion volume.

Route-specific release standards for SBECD-containing finished products are summarized below. The table is limited to tests commonly applied at batch release and does not replace product-specific marketing authorization or ANDA specifications.

Lyophilized SBECD formulations are chosen when the drug undergoes rapid hydrolysis in aqueous solution at pH 6–8 or when terminal sterilization is not feasible. In this configuration, SBECD is dissolved in the pre-lyophilization solution at 5%–30% w/v, and the drug is loaded at a molar ratio of 1:1 to 1:20. The solution is filled into 2R/6R/10R Type I borosilicate glass vials with a fill depth maintained below 8 mm to avoid sublimation arrest during primary drying. A production-scale lyophilizer with shelf temperature uniformity of ±2°C and a condenser capacity of at least 20 kg is used; the cycle typically includes freezing to −45°C at 0.5–1°C/min, an annealing step at −15°C to −10°C for 3–6 h to crystallize bulking agents, primary drying at a shelf temperature of −25°C to −15°C and chamber pressure of 50–100 mTorr, and secondary drying at 25–40°C for 6–12 h. The collapse temperature of SBECD-containing solutions is concentration-dependent; published freeze-dry microscopy data for 10% w/v aqueous SBECD generally show collapse above approximately −18°C, and formulation-specific Tg′ determination by DSC is required before scale-up. Vial-to-vial moisture content is controlled by USP <921> Method 1c, with acceptance routinely set at <1.0% w/w. Container closure integrity after stoppering is verified by vacuum decay or laser-based headspace analysis according to USP <1207>. This process yields sterile powder for injection, lyophilized powder for reconstitution, and intramuscular suspension precursors after reconstitution with WFI or sterile diluent containing a tonicity modifier. Batch records from commercial lines show that sublimation rate is frequently limited by vial heat transfer coefficient K_v values of 10–30 W/m²·K for 10 mL tubing vials; therefore edge-vial product temperature excursions must be monitored with thermocouples and Pirani gauges during primary drying.

Oral Tablet and Capsule Dissolution Limits for BCS Class II and IV Compounds

For BCS Class II and IV APIs with aqueous solubility below 10 µg/mL, SBECD is used as a carrier in wet granulation to produce an inclusion complex that increases intrinsic dissolution rate. The addition level in the granulation fluid is typically 5%–20% w/w of the total core tablet mass, and the API-to-SBECD molar ratio is maintained between 1:1 and 1:10. Ratios above 1:20 rarely improve dissolution further because the tablet matrix can become hygroscopic and sticky above 60% RH. The granulation process employs a high-shear granulator with impeller speed 200–400 rpm and chopper speed 1000–1500 rpm, or a fluid-bed granulator with inlet air temperature 60–70°C and product temperature 30–40°C. The resulting granules are dried to a loss-on-drying specification of 1.0%–3.0% w/w, then milled through a 0.8–1.25 mm conical mill screen. Tablets are compressed on a rotary tablet press with main compression force 8–20 kN and precompression force 2–5 kN; capsules are filled using a dosator or tamping machine with fill weight verified by USP <905> uniformity of dosage units. Dissolution testing follows USP <711> Apparatus II at 50–75 rpm; when the complex is formed before granulation, the dissolution Q point can shift from 30 min to 15 min for the same API load. Terminal finished product types include immediate-release tablets, hard gelatin capsules, and granule-filled sachets for reconstitution. In-process controls must include particle size distribution after milling because SBECD-containing granulates can exhibit bulk density variation of 0.45–0.65 g/mL depending on spray rate and drying endpoint. Published data for specific approved oral SBECD products is limited compared with injectable products; development reports therefore rely on preformulation phase-solubility data rather than compendial monograph examples.

The formulation ratio ranges and critical processing boundaries for the principal SBECD-enabled dosage forms are compared below.

What Changes When SBECD Granules Are Produced by Fluid-Bed Layering for Pediatric Dosing?

Pediatric sachet products require precise low-dose uniformity and dispersibility. SBECD is applied as a binder in fluid-bed top-spray granulation at 10%–25% w/w of the final granule mass, with API-to-SBECD molar ratios typically 1:5 to 1:15. The layering solution is prepared at 15%–25% w/v SBECD in purified water, and spray rate is maintained at 5–15 g/min/kg of substrate; inlet air temperature is 55–75°C, and product temperature is controlled at 28–35°C to avoid glass transition softening of the cyclodextrin matrix. After drying, granules are sieved to 125–500 µm and filled into aluminum sachets under 25% RH or lower. The finished product types are single-dose pediatric oral granules, dispersible granules for suspension, and sprinkle capsules. Compliance testing includes USP <905>, USP <711>, USP <701> disintegration, and Ph. Eur. 2.9.3 for products registered in European jurisdictions. Because pediatric dosing often requires body-weight adjustment, the granule fraction must demonstrate mass uniformity below 5% RSD across 10 consecutive sachets. The main processing boundary is hygroscopicity: at RH >60%, SBECD granules can absorb moisture above 5% w/w in 2 h and cake during storage; primary packaging must therefore provide a water vapor transmission rate below 0.5 g/m²/day at 25°C/75% RH. Taste-masking by inclusion complexation is not universal; efficacy depends on the API binding constant and the degree of complexation in the granule, which is measured by differential scanning calorimetry or phase-solubility analysis. Published data for specific marketed SBECD pediatric granules is limited; package development should therefore include accelerated stability at 40°C/75% RH for 6 months to establish moisture uptake boundaries.

Oral liquid vehicles containing SBECD are prepared for poorly water-soluble APIs requiring dose flexibility for geriatric or dysphagic patients. The liquid concentrate contains SBECD at 5%–30% w/v, with API-to-SBECD molar ratio from 1:1 to 1:20, and the vehicle pH is adjusted to 3.0–8.0 with citrate or phosphate buffer. The production sequence uses a high-torque overhead mixer to disperse SBECD in purified water at 20–30°C; the API is then pre-wetted with 0.1–0.5% w/v poloxamer or polysorbate only if surface wetting is insufficient. Surfactant addition is minimized because surfactants compete with the cyclodextrin cavity and can reduce complexation efficiency. The solution is clarified through a 0.45 µm filter and filled into amber Type III glass bottles or polyethylene terephthalate bottles. Terminal liquid oral dosage forms include oral drops, oral solutions, and reconstitutable suspensions; if a suspension is manufactured, a high-pressure homogenizer at 500–1000 bar is used to reduce particle size to D90 <10 µm. Microbiological testing follows USP <1111> acceptance criteria for nonsterile products, and preservative efficacy testing follows USP <51>. Chemical stability is influenced by the unfilled SBECD fraction; a molar ratio at or above saturation binding is typically required to prevent API recrystallization after storage at 25°C/60% RH for 12 months. The operational limitation of SBECD in oral liquids is the viscosity increase above 35% w/v, which impairs filter throughput and requires positive-displacement pumps rather than centrifugal pumps. Batch-to-batch variation in the degree of substitution may cause small shifts in osmolality; therefore osmolality testing per USP <785> is included in release for pediatric oral solutions, with a range commonly set at 250–350 mOsm/kg.

Ophthalmic Tonicity and Corneal Contact Time Boundaries in SBECD-Containing Sterile Drops

SBECD is used in ophthalmic formulations at 1%–10% w/v for poorly water-soluble ophthalmic APIs, with the API-to-SBECD molar ratio typically between 1:5 and 1:25. The formulation is buffered to pH 6.5–7.8 with phosphate or borate buffer, and tonicity is adjusted to 280–320 mOsm/kg with sodium chloride, mannitol, or glycerin; direct replacement of buffer salts must account for the contribution of SBECD sodium counterions, which can add 20–60 mOsm/kg at higher concentrations. Sterile filtration through 0.22 µm PES or polyvinylidene fluoride membranes per ASTM F838-20 is followed by filling into blow-fill-seal unit-dose LDPE ampoules or multi-dose bottles with preservative. If multi-dose packaging is used, preservative efficacy testing per USP <51> is required because SBECD can bind benzalkonium chloride and reduce preservative availability. Terminal finishing includes autoclaving at 121.1°C for 15 min when the API and container are heat-stable; otherwise, aseptic processing under EU GMP Annex 1 is used. The finished product types are sterile ophthalmic solutions, unit-dose eye drops, and ocular irrigation solutions. Release standards include USP <771> for ophthalmic preparations, USP <71> sterility, USP <85> bacterial endotoxins, and particulate testing per USP <788> adapted for small-volume ophthalmic products. The primary boundary condition is ocular residence time; SBECD does not act as a mucoadhesive, so the tear-turnover half-life of approximately 5–15 min under normal blinking remains the limiting factor for bioavailability. Published data on corneal permeation enhancement by SBECD is formulation-specific, and no generalized claim of increased intraocular penetration should be made without isolated corneal tissue permeation testing. Production lines must exclude cationic preservatives that form insoluble complexes with sulfobutyl ether groups; anionic polyelectrolyte interactions can also increase turbidity and should be assessed by zeta potential measurement, with a target absolute zeta potential above 30 mV for suspension-type ophthalmic products.